Compare Raytheon Technologies Corp (RTX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raytheon Technologies Corp vs Recursion Pharmaceuticals Inc — how do they compare? Raytheon Technologies Corp trades at $193.75 (market cap $261.85B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Raytheon Technologies Corp is far larger — about 171.1× Recursion Pharmaceuticals Inc's market cap, and Raytheon Technologies Corp pays a 1.5% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RTX | RXRX | |
|---|---|---|
Market Cap | $261.85B | $1.53B |
Sector | Industrials | Health |
52-Week High | $212.16 | $6.79 |
52-Week Low | $149.17 | $2.84 |
Enterprise Value | $293.97B | $946.50M |
Dividend Yield | 1.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RTX trades at $193.51, down 0.44% today, with a bullish technical signal and strong analyst support. Recent contract wins, including a $515 million Navy radar deal (PRNewsWire, June 3, 2026), and earnings beats in Q4 2025 and Q1 2026 highlight operational momentum. Revenue growth accelerated to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock faces resistance near $196-$199, with support at $192.
The outlook remains positive given defense spending tailwinds and production expansions, but elevated P/E of 36.48 poses valuation risk. Analysts project 10% upside to a $213 consensus target, with no sell ratings. Key risks include debt levels and geopolitical volatility affecting contracts.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
